Barclays PLC Invests $215,000 in Electromed, Inc. (NYSE:ELMD)

Barclays PLC acquired a new position in Electromed, Inc. (NYSE:ELMD) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,022 shares of the company’s stock, valued at approximately $215,000. Barclays PLC owned approximately 0.12% of Electromed at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Marshall Wace LLP purchased a new stake in Electromed in the 2nd quarter worth $256,000. Walleye Capital LLC purchased a new position in shares of Electromed during the third quarter valued at about $274,000. Navellier & Associates Inc. purchased a new position in shares of Electromed during the third quarter valued at about $368,000. State Street Corp grew its position in shares of Electromed by 14.5% during the third quarter. State Street Corp now owns 22,066 shares of the company’s stock valued at $474,000 after purchasing an additional 2,800 shares in the last quarter. Finally, Pekin Hardy Strauss Inc. purchased a new position in shares of Electromed during the second quarter valued at about $522,000. 40.82% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Electromed

In other Electromed news, Director Andrew Summers sold 17,463 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $30.09, for a total value of $525,461.67. Following the completion of the sale, the director now owns 189,838 shares of the company’s stock, valued at $5,712,225.42. This trade represents a 8.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 14.00% of the stock is owned by insiders.

Electromed Stock Up 1.8 %

Shares of Electromed stock opened at $31.23 on Tuesday. The firm has a market cap of $264.14 million, a price-to-earnings ratio of 43.38 and a beta of 0.31. The business has a 50-day moving average price of $28.08 and a 200-day moving average price of $21.23. Electromed, Inc. has a twelve month low of $9.81 and a twelve month high of $31.88.

Electromed (NYSE:ELMD) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.13. Electromed had a net margin of 11.34% and a return on equity of 15.32%. The firm had revenue of $14.67 million during the quarter.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.